BICYCLE THERAPEUTICS PLC Quarterly Nonoperating Income (Expense) in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Bicycle Therapeutics Plc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2018 to Q2 2024.
  • Bicycle Therapeutics Plc Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $6.95M.
  • Bicycle Therapeutics Plc Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $20.4M, a 300% increase year-over-year.
  • Bicycle Therapeutics Plc annual Nonoperating Income (Expense) for 2023 was $10.7M, a 345% increase from 2022.
  • Bicycle Therapeutics Plc annual Nonoperating Income (Expense) for 2022 was $2.41M.
  • Bicycle Therapeutics Plc annual Nonoperating Income (Expense) for 2021 was -$2.86M, a 1367% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $20.4M $6.95M +$6.96M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $13.4M $4.8M +$2.68M +126% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $10.7M $5.46M +$3.64M +201% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $7.1M $3.17M +$2M +170% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $5.1M -$9K -$34K -136% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $5.13M $2.12M +$2.72M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $2.41M $1.81M +$2.58M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 -$163K $1.17M +$1.97M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$2.14M $25K +$821K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$2.96M -$600K -$93K -18.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$2.86M -$762K -$333K -77.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 -$2.53M -$799K -$871K -1210% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$1.66M -$796K -$1.17M -315% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$493K -$507K -$719K -339% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $226K -$429K -$649K -295% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-11
Q3 2020 $875K $72K -$368K -83.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $1.24M $371K +$2.47M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$1.22M $212K +$3.34M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$4.56M $220K -$681K -75.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$3.88M $440K +$1.78M Jul 1, 2019 Sep 30, 2019 10-K 2021-03-11
Q2 2019 -$5.66M -$2.09M -$2.07M -9871% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-11
Q1 2019 -$3.58M -$3.13M -$3.09M -7532% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-11
Q4 2018 -$496K $901K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$1.34M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-10
Q2 2018 -$21K Apr 1, 2018 Jun 30, 2018 10-K 2020-03-10
Q1 2018 -$41K Jan 1, 2018 Mar 31, 2018 10-K 2020-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.